Table 3. Distribution of drug resistance in different spectrum of infection.
| Sr. no. | Clinical condition | Number (%) of clinically significant culture isolates | ||||
|---|---|---|---|---|---|---|
| NMDR | MDR | P-XDR | Total | |||
| Abbreviations: CAP, community-acquired pneumonia; CA-UTI, catheter-associated urinary tract infection; CLABSI, central line-associated blood stream infection; HAP, hospital-acquired pneumonia; MDR, multidrug resistant; NMDR,nonmultidrug resistant; P-XDR, possible extensive drug resistant; PBSI, primary blood stream infection; S-BSI, secondary blood stream infection; S-UTI, symptomatic urinary tract infection; SSTI, skin and soft tissue infection; VAP, Ventilator associated pneumonia. Note: p -value < 0.001 by Fisher's exact t -test suggesting significant association between occurrence of RTI, UTI, BSI, and others site infection with NMDR, MDR, and P-XDR isolates. | ||||||
| A. | 1. Respiratory tract infection | 12 | 17 | 110 | 139 (43%) | p -value< 0.001 |
| 1.1 CAP | 3 | 1 | 0 | 4 | – | |
| 1.2 HAP | 5 | 3 | 24 | 32 | ||
| 1.3 VAP | 0 | 13 | 82 | 95 | ||
| 1.4 Pleural fluid | 4 | 0 | 4 | 8 | ||
| B. | 2. Urinary tract infection | 11 | 41 | 30 | 82 (25%) | p -value = 0.01 |
| 2.1 S-UTI | 8 | 20 | 7 | 35 | – | |
| 2.2 CA-UTI | 3 | 21 | 23 | 47 | ||
| C. | 3. Blood stream infection | 2 | 29 | 42 | 73(22.6%) | p -value = 0.248 |
| 3.1 P-BSI | 2 | 13 | 15 | 30 | – | |
| 3.2 S-BSI | 0 | 13 | 16 | 29 | ||
| 3.3 CLABSI | 0 | 3 | 11 | 14 | ||
| D. | 4. Others | 5 | 9 | 15 | 29 (8%) | p -value = 0.803 |
| 4.1 SSTI | 5 | 6 | 10 | 21 | – | |
| 4.2 Meningitis | 0 | 1 | 3 | 4 | ||
| 4.3 Cholangitis | 0 | 1 | 0 | 1 | ||
| 4.4 Peritonitis | 0 | 1 | 2 | 3 | ||